nodes	percent_of_prediction	percent_of_DWPC	metapath
Milnacipran—Hot flush—Doxorubicin—sarcoma	0.00264	0.00264	CcSEcCtD
Milnacipran—Hypotension—Mitoxantrone—sarcoma	0.00263	0.00263	CcSEcCtD
Milnacipran—Migraine—Epirubicin—sarcoma	0.00263	0.00263	CcSEcCtD
Milnacipran—Menopausal symptoms—Doxorubicin—sarcoma	0.00262	0.00262	CcSEcCtD
Milnacipran—Insomnia—Vincristine—sarcoma	0.00262	0.00262	CcSEcCtD
Milnacipran—Paraesthesia—Vincristine—sarcoma	0.0026	0.0026	CcSEcCtD
Milnacipran—Urticaria—Thiotepa—sarcoma	0.00259	0.00259	CcSEcCtD
Milnacipran—Abdominal pain—Thiotepa—sarcoma	0.00258	0.00258	CcSEcCtD
Milnacipran—Body temperature increased—Thiotepa—sarcoma	0.00258	0.00258	CcSEcCtD
Milnacipran—Leukopenia—Etoposide—sarcoma	0.00257	0.00257	CcSEcCtD
Milnacipran—Abdominal pain—Dactinomycin—sarcoma	0.00256	0.00256	CcSEcCtD
Milnacipran—Body temperature increased—Dactinomycin—sarcoma	0.00256	0.00256	CcSEcCtD
Milnacipran—Paraesthesia—Mitoxantrone—sarcoma	0.00253	0.00253	CcSEcCtD
Milnacipran—Loss of consciousness—Etoposide—sarcoma	0.00252	0.00252	CcSEcCtD
Milnacipran—Decreased appetite—Vincristine—sarcoma	0.00251	0.00251	CcSEcCtD
Milnacipran—Dyspnoea—Mitoxantrone—sarcoma	0.00251	0.00251	CcSEcCtD
Milnacipran—Somnolence—Mitoxantrone—sarcoma	0.0025	0.0025	CcSEcCtD
Milnacipran—Gastrointestinal disorder—Vincristine—sarcoma	0.0025	0.0025	CcSEcCtD
Milnacipran—Fatigue—Vincristine—sarcoma	0.00249	0.00249	CcSEcCtD
Milnacipran—Convulsion—Etoposide—sarcoma	0.00249	0.00249	CcSEcCtD
Milnacipran—Hyponatraemia—Doxorubicin—sarcoma	0.00248	0.00248	CcSEcCtD
Milnacipran—Dyspepsia—Mitoxantrone—sarcoma	0.00248	0.00248	CcSEcCtD
Milnacipran—Hypertension—Etoposide—sarcoma	0.00248	0.00248	CcSEcCtD
Milnacipran—Constipation—Vincristine—sarcoma	0.00247	0.00247	CcSEcCtD
Milnacipran—Liver function test abnormal—Epirubicin—sarcoma	0.00247	0.00247	CcSEcCtD
Milnacipran—Dry skin—Epirubicin—sarcoma	0.00245	0.00245	CcSEcCtD
Milnacipran—Decreased appetite—Mitoxantrone—sarcoma	0.00245	0.00245	CcSEcCtD
Milnacipran—Chest pain—Etoposide—sarcoma	0.00244	0.00244	CcSEcCtD
Milnacipran—Migraine—Doxorubicin—sarcoma	0.00243	0.00243	CcSEcCtD
Milnacipran—Fatigue—Mitoxantrone—sarcoma	0.00243	0.00243	CcSEcCtD
Milnacipran—Unspecified disorder of skin and subcutaneous tissue—Etoposide—sarcoma	0.00243	0.00243	CcSEcCtD
Milnacipran—Breast disorder—Epirubicin—sarcoma	0.00241	0.00241	CcSEcCtD
Milnacipran—Constipation—Mitoxantrone—sarcoma	0.00241	0.00241	CcSEcCtD
Milnacipran—Hypersensitivity—Thiotepa—sarcoma	0.0024	0.0024	CcSEcCtD
Milnacipran—Hypersensitivity—Dactinomycin—sarcoma	0.00239	0.00239	CcSEcCtD
Milnacipran—Gastrointestinal pain—Vincristine—sarcoma	0.00237	0.00237	CcSEcCtD
Milnacipran—Asthenia—Thiotepa—sarcoma	0.00234	0.00234	CcSEcCtD
Milnacipran—Infection—Etoposide—sarcoma	0.00233	0.00233	CcSEcCtD
Milnacipran—Abdominal distension—Epirubicin—sarcoma	0.00232	0.00232	CcSEcCtD
Milnacipran—Asthenia—Dactinomycin—sarcoma	0.00232	0.00232	CcSEcCtD
Milnacipran—Pruritus—Thiotepa—sarcoma	0.00231	0.00231	CcSEcCtD
Milnacipran—Gastrointestinal pain—Mitoxantrone—sarcoma	0.0023	0.0023	CcSEcCtD
Milnacipran—Thrombocytopenia—Etoposide—sarcoma	0.00229	0.00229	CcSEcCtD
Milnacipran—Tachycardia—Etoposide—sarcoma	0.00229	0.00229	CcSEcCtD
Milnacipran—Body temperature increased—Vincristine—sarcoma	0.00229	0.00229	CcSEcCtD
Milnacipran—Abdominal pain—Vincristine—sarcoma	0.00229	0.00229	CcSEcCtD
Milnacipran—Liver function test abnormal—Doxorubicin—sarcoma	0.00228	0.00228	CcSEcCtD
Milnacipran—Skin disorder—Etoposide—sarcoma	0.00228	0.00228	CcSEcCtD
Milnacipran—Dry skin—Doxorubicin—sarcoma	0.00227	0.00227	CcSEcCtD
Milnacipran—Hyperhidrosis—Etoposide—sarcoma	0.00226	0.00226	CcSEcCtD
Milnacipran—Angina pectoris—Epirubicin—sarcoma	0.00225	0.00225	CcSEcCtD
Milnacipran—Urticaria—Mitoxantrone—sarcoma	0.00224	0.00224	CcSEcCtD
Milnacipran—Breast disorder—Doxorubicin—sarcoma	0.00223	0.00223	CcSEcCtD
Milnacipran—Anorexia—Etoposide—sarcoma	0.00223	0.00223	CcSEcCtD
Milnacipran—Diarrhoea—Thiotepa—sarcoma	0.00223	0.00223	CcSEcCtD
Milnacipran—Abdominal pain—Mitoxantrone—sarcoma	0.00223	0.00223	CcSEcCtD
Milnacipran—Body temperature increased—Mitoxantrone—sarcoma	0.00223	0.00223	CcSEcCtD
Milnacipran—Diarrhoea—Dactinomycin—sarcoma	0.00221	0.00221	CcSEcCtD
Milnacipran—Hypotension—Etoposide—sarcoma	0.00219	0.00219	CcSEcCtD
Milnacipran—Neutropenia—Epirubicin—sarcoma	0.00216	0.00216	CcSEcCtD
Milnacipran—Dysuria—Epirubicin—sarcoma	0.00216	0.00216	CcSEcCtD
Milnacipran—Dizziness—Thiotepa—sarcoma	0.00216	0.00216	CcSEcCtD
Milnacipran—Abdominal distension—Doxorubicin—sarcoma	0.00215	0.00215	CcSEcCtD
Milnacipran—Upper respiratory tract infection—Epirubicin—sarcoma	0.00215	0.00215	CcSEcCtD
Milnacipran—Pollakiuria—Epirubicin—sarcoma	0.00213	0.00213	CcSEcCtD
Milnacipran—Hypersensitivity—Vincristine—sarcoma	0.00213	0.00213	CcSEcCtD
Milnacipran—Paraesthesia—Etoposide—sarcoma	0.0021	0.0021	CcSEcCtD
Milnacipran—Weight decreased—Epirubicin—sarcoma	0.00209	0.00209	CcSEcCtD
Milnacipran—Dyspnoea—Etoposide—sarcoma	0.00209	0.00209	CcSEcCtD
Milnacipran—Somnolence—Etoposide—sarcoma	0.00208	0.00208	CcSEcCtD
Milnacipran—Angina pectoris—Doxorubicin—sarcoma	0.00208	0.00208	CcSEcCtD
Milnacipran—Hypersensitivity—Mitoxantrone—sarcoma	0.00208	0.00208	CcSEcCtD
Milnacipran—Asthenia—Vincristine—sarcoma	0.00208	0.00208	CcSEcCtD
Milnacipran—Vomiting—Thiotepa—sarcoma	0.00207	0.00207	CcSEcCtD
Milnacipran—Vomiting—Dactinomycin—sarcoma	0.00206	0.00206	CcSEcCtD
Milnacipran—Rash—Thiotepa—sarcoma	0.00206	0.00206	CcSEcCtD
Milnacipran—Dermatitis—Thiotepa—sarcoma	0.00205	0.00205	CcSEcCtD
Milnacipran—Headache—Thiotepa—sarcoma	0.00204	0.00204	CcSEcCtD
Milnacipran—Stevens-Johnson syndrome—Epirubicin—sarcoma	0.00204	0.00204	CcSEcCtD
Milnacipran—Rash—Dactinomycin—sarcoma	0.00204	0.00204	CcSEcCtD
Milnacipran—Decreased appetite—Etoposide—sarcoma	0.00204	0.00204	CcSEcCtD
Milnacipran—Gastrointestinal disorder—Etoposide—sarcoma	0.00202	0.00202	CcSEcCtD
Milnacipran—Asthenia—Mitoxantrone—sarcoma	0.00202	0.00202	CcSEcCtD
Milnacipran—Fatigue—Etoposide—sarcoma	0.00202	0.00202	CcSEcCtD
Milnacipran—Constipation—Etoposide—sarcoma	0.002	0.002	CcSEcCtD
Milnacipran—Urinary tract infection—Epirubicin—sarcoma	0.002	0.002	CcSEcCtD
Milnacipran—Dysuria—Doxorubicin—sarcoma	0.002	0.002	CcSEcCtD
Milnacipran—Neutropenia—Doxorubicin—sarcoma	0.002	0.002	CcSEcCtD
Milnacipran—Upper respiratory tract infection—Doxorubicin—sarcoma	0.00199	0.00199	CcSEcCtD
Milnacipran—Diarrhoea—Vincristine—sarcoma	0.00198	0.00198	CcSEcCtD
Milnacipran—Pollakiuria—Doxorubicin—sarcoma	0.00197	0.00197	CcSEcCtD
Milnacipran—Haematuria—Epirubicin—sarcoma	0.00196	0.00196	CcSEcCtD
Milnacipran—Hepatobiliary disease—Epirubicin—sarcoma	0.00195	0.00195	CcSEcCtD
Milnacipran—Nausea—Thiotepa—sarcoma	0.00194	0.00194	CcSEcCtD
Milnacipran—Weight decreased—Doxorubicin—sarcoma	0.00193	0.00193	CcSEcCtD
Milnacipran—Diarrhoea—Mitoxantrone—sarcoma	0.00193	0.00193	CcSEcCtD
Milnacipran—Nausea—Dactinomycin—sarcoma	0.00192	0.00192	CcSEcCtD
Milnacipran—Gastrointestinal pain—Etoposide—sarcoma	0.00192	0.00192	CcSEcCtD
Milnacipran—Dizziness—Vincristine—sarcoma	0.00191	0.00191	CcSEcCtD
Milnacipran—Stevens-Johnson syndrome—Doxorubicin—sarcoma	0.00189	0.00189	CcSEcCtD
Milnacipran—Urticaria—Etoposide—sarcoma	0.00186	0.00186	CcSEcCtD
Milnacipran—Abdominal pain—Etoposide—sarcoma	0.00185	0.00185	CcSEcCtD
Milnacipran—Body temperature increased—Etoposide—sarcoma	0.00185	0.00185	CcSEcCtD
Milnacipran—Urinary tract infection—Doxorubicin—sarcoma	0.00185	0.00185	CcSEcCtD
Milnacipran—Hepatitis—Epirubicin—sarcoma	0.00185	0.00185	CcSEcCtD
Milnacipran—Hypoaesthesia—Epirubicin—sarcoma	0.00184	0.00184	CcSEcCtD
Milnacipran—Vomiting—Vincristine—sarcoma	0.00184	0.00184	CcSEcCtD
Milnacipran—Urinary tract disorder—Epirubicin—sarcoma	0.00183	0.00183	CcSEcCtD
Milnacipran—Rash—Vincristine—sarcoma	0.00182	0.00182	CcSEcCtD
Milnacipran—Dermatitis—Vincristine—sarcoma	0.00182	0.00182	CcSEcCtD
Milnacipran—Oedema peripheral—Epirubicin—sarcoma	0.00182	0.00182	CcSEcCtD
Milnacipran—Haematuria—Doxorubicin—sarcoma	0.00182	0.00182	CcSEcCtD
Milnacipran—Connective tissue disorder—Epirubicin—sarcoma	0.00182	0.00182	CcSEcCtD
Milnacipran—Urethral disorder—Epirubicin—sarcoma	0.00181	0.00181	CcSEcCtD
Milnacipran—Headache—Vincristine—sarcoma	0.00181	0.00181	CcSEcCtD
Milnacipran—Hepatobiliary disease—Doxorubicin—sarcoma	0.0018	0.0018	CcSEcCtD
Milnacipran—Vomiting—Mitoxantrone—sarcoma	0.00179	0.00179	CcSEcCtD
Milnacipran—Rash—Mitoxantrone—sarcoma	0.00178	0.00178	CcSEcCtD
Milnacipran—Dermatitis—Mitoxantrone—sarcoma	0.00177	0.00177	CcSEcCtD
Milnacipran—Headache—Mitoxantrone—sarcoma	0.00176	0.00176	CcSEcCtD
Milnacipran—Erythema multiforme—Epirubicin—sarcoma	0.00175	0.00175	CcSEcCtD
Milnacipran—Eye disorder—Epirubicin—sarcoma	0.00173	0.00173	CcSEcCtD
Milnacipran—Hypersensitivity—Etoposide—sarcoma	0.00173	0.00173	CcSEcCtD
Milnacipran—Nausea—Vincristine—sarcoma	0.00172	0.00172	CcSEcCtD
Milnacipran—Flushing—Epirubicin—sarcoma	0.00172	0.00172	CcSEcCtD
Milnacipran—Cardiac disorder—Epirubicin—sarcoma	0.00172	0.00172	CcSEcCtD
Milnacipran—Hepatitis—Doxorubicin—sarcoma	0.00171	0.00171	CcSEcCtD
Milnacipran—Hypoaesthesia—Doxorubicin—sarcoma	0.0017	0.0017	CcSEcCtD
Milnacipran—Urinary tract disorder—Doxorubicin—sarcoma	0.00169	0.00169	CcSEcCtD
Milnacipran—Oedema peripheral—Doxorubicin—sarcoma	0.00168	0.00168	CcSEcCtD
Milnacipran—Asthenia—Etoposide—sarcoma	0.00168	0.00168	CcSEcCtD
Milnacipran—Connective tissue disorder—Doxorubicin—sarcoma	0.00168	0.00168	CcSEcCtD
Milnacipran—Angiopathy—Epirubicin—sarcoma	0.00168	0.00168	CcSEcCtD
Milnacipran—Urethral disorder—Doxorubicin—sarcoma	0.00168	0.00168	CcSEcCtD
Milnacipran—Nausea—Mitoxantrone—sarcoma	0.00167	0.00167	CcSEcCtD
Milnacipran—Mediastinal disorder—Epirubicin—sarcoma	0.00167	0.00167	CcSEcCtD
Milnacipran—Chills—Epirubicin—sarcoma	0.00166	0.00166	CcSEcCtD
Milnacipran—Pruritus—Etoposide—sarcoma	0.00166	0.00166	CcSEcCtD
Milnacipran—Mental disorder—Epirubicin—sarcoma	0.00162	0.00162	CcSEcCtD
Milnacipran—Erythema multiforme—Doxorubicin—sarcoma	0.00162	0.00162	CcSEcCtD
Milnacipran—Malnutrition—Epirubicin—sarcoma	0.00161	0.00161	CcSEcCtD
Milnacipran—Diarrhoea—Etoposide—sarcoma	0.0016	0.0016	CcSEcCtD
Milnacipran—Eye disorder—Doxorubicin—sarcoma	0.0016	0.0016	CcSEcCtD
Milnacipran—Cardiac disorder—Doxorubicin—sarcoma	0.00159	0.00159	CcSEcCtD
Milnacipran—Flushing—Doxorubicin—sarcoma	0.00159	0.00159	CcSEcCtD
Milnacipran—Flatulence—Epirubicin—sarcoma	0.00159	0.00159	CcSEcCtD
Milnacipran—Tension—Epirubicin—sarcoma	0.00158	0.00158	CcSEcCtD
Milnacipran—Dysgeusia—Epirubicin—sarcoma	0.00158	0.00158	CcSEcCtD
Milnacipran—Angiopathy—Doxorubicin—sarcoma	0.00155	0.00155	CcSEcCtD
Milnacipran—Dizziness—Etoposide—sarcoma	0.00155	0.00155	CcSEcCtD
Milnacipran—Mediastinal disorder—Doxorubicin—sarcoma	0.00154	0.00154	CcSEcCtD
Milnacipran—Chills—Doxorubicin—sarcoma	0.00153	0.00153	CcSEcCtD
Milnacipran—Vision blurred—Epirubicin—sarcoma	0.00152	0.00152	CcSEcCtD
Milnacipran—Mental disorder—Doxorubicin—sarcoma	0.0015	0.0015	CcSEcCtD
Milnacipran—Vomiting—Etoposide—sarcoma	0.00149	0.00149	CcSEcCtD
Milnacipran—Malnutrition—Doxorubicin—sarcoma	0.00149	0.00149	CcSEcCtD
Milnacipran—Agitation—Epirubicin—sarcoma	0.00148	0.00148	CcSEcCtD
Milnacipran—Rash—Etoposide—sarcoma	0.00148	0.00148	CcSEcCtD
Milnacipran—Dermatitis—Etoposide—sarcoma	0.00148	0.00148	CcSEcCtD
Milnacipran—Headache—Etoposide—sarcoma	0.00147	0.00147	CcSEcCtD
Milnacipran—Flatulence—Doxorubicin—sarcoma	0.00147	0.00147	CcSEcCtD
Milnacipran—Tension—Doxorubicin—sarcoma	0.00146	0.00146	CcSEcCtD
Milnacipran—Dysgeusia—Doxorubicin—sarcoma	0.00146	0.00146	CcSEcCtD
Milnacipran—Syncope—Epirubicin—sarcoma	0.00144	0.00144	CcSEcCtD
Milnacipran—Leukopenia—Epirubicin—sarcoma	0.00144	0.00144	CcSEcCtD
Milnacipran—Palpitations—Epirubicin—sarcoma	0.00142	0.00142	CcSEcCtD
Milnacipran—Loss of consciousness—Epirubicin—sarcoma	0.00141	0.00141	CcSEcCtD
Milnacipran—Vision blurred—Doxorubicin—sarcoma	0.0014	0.0014	CcSEcCtD
Milnacipran—Convulsion—Epirubicin—sarcoma	0.00139	0.00139	CcSEcCtD
Milnacipran—Nausea—Etoposide—sarcoma	0.00139	0.00139	CcSEcCtD
Milnacipran—Hypertension—Epirubicin—sarcoma	0.00139	0.00139	CcSEcCtD
Milnacipran—Chest pain—Epirubicin—sarcoma	0.00137	0.00137	CcSEcCtD
Milnacipran—Agitation—Doxorubicin—sarcoma	0.00137	0.00137	CcSEcCtD
Milnacipran—Anxiety—Epirubicin—sarcoma	0.00137	0.00137	CcSEcCtD
Milnacipran—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—sarcoma	0.00136	0.00136	CcSEcCtD
Milnacipran—Dry mouth—Epirubicin—sarcoma	0.00134	0.00134	CcSEcCtD
Milnacipran—Syncope—Doxorubicin—sarcoma	0.00134	0.00134	CcSEcCtD
Milnacipran—Leukopenia—Doxorubicin—sarcoma	0.00133	0.00133	CcSEcCtD
Milnacipran—Palpitations—Doxorubicin—sarcoma	0.00132	0.00132	CcSEcCtD
Milnacipran—Loss of consciousness—Doxorubicin—sarcoma	0.00131	0.00131	CcSEcCtD
Milnacipran—Infection—Epirubicin—sarcoma	0.0013	0.0013	CcSEcCtD
Milnacipran—Shock—Epirubicin—sarcoma	0.00129	0.00129	CcSEcCtD
Milnacipran—Convulsion—Doxorubicin—sarcoma	0.00129	0.00129	CcSEcCtD
Milnacipran—Nervous system disorder—Epirubicin—sarcoma	0.00129	0.00129	CcSEcCtD
Milnacipran—Thrombocytopenia—Epirubicin—sarcoma	0.00129	0.00129	CcSEcCtD
Milnacipran—Hypertension—Doxorubicin—sarcoma	0.00129	0.00129	CcSEcCtD
Milnacipran—Tachycardia—Epirubicin—sarcoma	0.00128	0.00128	CcSEcCtD
Milnacipran—Skin disorder—Epirubicin—sarcoma	0.00128	0.00128	CcSEcCtD
Milnacipran—Hyperhidrosis—Epirubicin—sarcoma	0.00127	0.00127	CcSEcCtD
Milnacipran—Chest pain—Doxorubicin—sarcoma	0.00127	0.00127	CcSEcCtD
Milnacipran—Anxiety—Doxorubicin—sarcoma	0.00126	0.00126	CcSEcCtD
Milnacipran—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—sarcoma	0.00126	0.00126	CcSEcCtD
Milnacipran—Anorexia—Epirubicin—sarcoma	0.00125	0.00125	CcSEcCtD
Milnacipran—Dry mouth—Doxorubicin—sarcoma	0.00124	0.00124	CcSEcCtD
Milnacipran—Hypotension—Epirubicin—sarcoma	0.00123	0.00123	CcSEcCtD
Milnacipran—Infection—Doxorubicin—sarcoma	0.00121	0.00121	CcSEcCtD
Milnacipran—Shock—Doxorubicin—sarcoma	0.0012	0.0012	CcSEcCtD
Milnacipran—Nervous system disorder—Doxorubicin—sarcoma	0.00119	0.00119	CcSEcCtD
Milnacipran—Thrombocytopenia—Doxorubicin—sarcoma	0.00119	0.00119	CcSEcCtD
Milnacipran—Insomnia—Epirubicin—sarcoma	0.00119	0.00119	CcSEcCtD
Milnacipran—Tachycardia—Doxorubicin—sarcoma	0.00119	0.00119	CcSEcCtD
Milnacipran—Skin disorder—Doxorubicin—sarcoma	0.00118	0.00118	CcSEcCtD
Milnacipran—Paraesthesia—Epirubicin—sarcoma	0.00118	0.00118	CcSEcCtD
Milnacipran—Hyperhidrosis—Doxorubicin—sarcoma	0.00117	0.00117	CcSEcCtD
Milnacipran—Dyspnoea—Epirubicin—sarcoma	0.00117	0.00117	CcSEcCtD
Milnacipran—Somnolence—Epirubicin—sarcoma	0.00117	0.00117	CcSEcCtD
Milnacipran—Anorexia—Doxorubicin—sarcoma	0.00116	0.00116	CcSEcCtD
Milnacipran—Dyspepsia—Epirubicin—sarcoma	0.00116	0.00116	CcSEcCtD
Milnacipran—Decreased appetite—Epirubicin—sarcoma	0.00114	0.00114	CcSEcCtD
Milnacipran—Hypotension—Doxorubicin—sarcoma	0.00114	0.00114	CcSEcCtD
Milnacipran—Gastrointestinal disorder—Epirubicin—sarcoma	0.00113	0.00113	CcSEcCtD
Milnacipran—Fatigue—Epirubicin—sarcoma	0.00113	0.00113	CcSEcCtD
Milnacipran—Constipation—Epirubicin—sarcoma	0.00112	0.00112	CcSEcCtD
Milnacipran—Insomnia—Doxorubicin—sarcoma	0.0011	0.0011	CcSEcCtD
Milnacipran—Paraesthesia—Doxorubicin—sarcoma	0.00109	0.00109	CcSEcCtD
Milnacipran—Dyspnoea—Doxorubicin—sarcoma	0.00108	0.00108	CcSEcCtD
Milnacipran—Somnolence—Doxorubicin—sarcoma	0.00108	0.00108	CcSEcCtD
Milnacipran—Gastrointestinal pain—Epirubicin—sarcoma	0.00107	0.00107	CcSEcCtD
Milnacipran—Dyspepsia—Doxorubicin—sarcoma	0.00107	0.00107	CcSEcCtD
Milnacipran—Decreased appetite—Doxorubicin—sarcoma	0.00106	0.00106	CcSEcCtD
Milnacipran—Gastrointestinal disorder—Doxorubicin—sarcoma	0.00105	0.00105	CcSEcCtD
Milnacipran—Fatigue—Doxorubicin—sarcoma	0.00105	0.00105	CcSEcCtD
Milnacipran—Urticaria—Epirubicin—sarcoma	0.00104	0.00104	CcSEcCtD
Milnacipran—Constipation—Doxorubicin—sarcoma	0.00104	0.00104	CcSEcCtD
Milnacipran—Abdominal pain—Epirubicin—sarcoma	0.00104	0.00104	CcSEcCtD
Milnacipran—Body temperature increased—Epirubicin—sarcoma	0.00104	0.00104	CcSEcCtD
Milnacipran—Gastrointestinal pain—Doxorubicin—sarcoma	0.000994	0.000994	CcSEcCtD
Milnacipran—Hypersensitivity—Epirubicin—sarcoma	0.000968	0.000968	CcSEcCtD
Milnacipran—Urticaria—Doxorubicin—sarcoma	0.000965	0.000965	CcSEcCtD
Milnacipran—Body temperature increased—Doxorubicin—sarcoma	0.000961	0.000961	CcSEcCtD
Milnacipran—Abdominal pain—Doxorubicin—sarcoma	0.000961	0.000961	CcSEcCtD
Milnacipran—Asthenia—Epirubicin—sarcoma	0.000942	0.000942	CcSEcCtD
Milnacipran—Pruritus—Epirubicin—sarcoma	0.000929	0.000929	CcSEcCtD
Milnacipran—Diarrhoea—Epirubicin—sarcoma	0.000899	0.000899	CcSEcCtD
Milnacipran—Hypersensitivity—Doxorubicin—sarcoma	0.000895	0.000895	CcSEcCtD
Milnacipran—Asthenia—Doxorubicin—sarcoma	0.000872	0.000872	CcSEcCtD
Milnacipran—Dizziness—Epirubicin—sarcoma	0.000868	0.000868	CcSEcCtD
Milnacipran—Pruritus—Doxorubicin—sarcoma	0.00086	0.00086	CcSEcCtD
Milnacipran—Vomiting—Epirubicin—sarcoma	0.000835	0.000835	CcSEcCtD
Milnacipran—Diarrhoea—Doxorubicin—sarcoma	0.000831	0.000831	CcSEcCtD
Milnacipran—Rash—Epirubicin—sarcoma	0.000828	0.000828	CcSEcCtD
Milnacipran—Dermatitis—Epirubicin—sarcoma	0.000827	0.000827	CcSEcCtD
Milnacipran—Headache—Epirubicin—sarcoma	0.000823	0.000823	CcSEcCtD
Milnacipran—Dizziness—Doxorubicin—sarcoma	0.000804	0.000804	CcSEcCtD
Milnacipran—Nausea—Epirubicin—sarcoma	0.00078	0.00078	CcSEcCtD
Milnacipran—Vomiting—Doxorubicin—sarcoma	0.000773	0.000773	CcSEcCtD
Milnacipran—Rash—Doxorubicin—sarcoma	0.000766	0.000766	CcSEcCtD
Milnacipran—Dermatitis—Doxorubicin—sarcoma	0.000765	0.000765	CcSEcCtD
Milnacipran—Headache—Doxorubicin—sarcoma	0.000761	0.000761	CcSEcCtD
Milnacipran—Nausea—Doxorubicin—sarcoma	0.000722	0.000722	CcSEcCtD
